See the Entire Portfolio

Unlearn

unlearn.ai

BioTech, HealthTech
B2B Current Investment

Unlearn.AI is the only company creating TwinRCTs™, which combine AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials. Unlearn’s technology has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. Unlearn is partnering with the world’s leading pharma companies, including Merck KGaA, Darmstadt, Germany, and continues to have discussions with regulators. The European Medicines Agency (EMA) published a draft qualification opinion for PROCOVA™ — a patent-pending method developed by Unlearn for leveraging historical data and machine learning to reduce sample sizes or increase power in Phase 2 or 3 clinical trials. For more information, please visit https://www.unlearn.ai or follow @UnlearnAI on Twitter, @unlearn-ai on LinkedIn.

News from Unlearn: